$KDS #Kiadis Pharma ... Morning Note: KDS NA, REC BB: Kiadis: NK cells as the next frontier in immunotherapy Recticel: 2Q revenue -33%, adjusted EBITDA slightly positive https://t.co/Uk5UIW4vAh #equity #stocks